» Articles » PMID: 8524126

Biological Assays for Ras Transformation

Overview
Journal Methods Enzymol
Specialty Biochemistry
Date 1995 Jan 1
PMID 8524126
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

The rodent fibroblast systems described above have provided sensitive and rapid biological assays to characterize the properties of normal and mutated Ras proteins. Furthermore, these assays have provided in vitro systems to measure the ability of other cellular components to modulate Ras signal transduction and transformation. However, while these assays provide an excellent measure of Ras-transforming activity, the fact that these cells are of fibroblastic origin, and can be transformed by a single hit, indicates that caution should be used in extrapolating observations from NIH 3T3 transformation assays to the situation in human tumors. Therefore, using human epithelial cell-based assays that more closely approximate the cell types where mutated ras alleles are most frequently detected may provide more realistic assays for examining the biochemical and biological consequences of aberrant Ras function in human tumors. Nevertheless, despite these cautions, these rodent transformation assays will continue to be the best and most widely applied assays for Ras biological activity.

Citing Articles

Transmembrane prostatic acid phosphatase: a therapeutic target in advanced prostate cancer.

Kirschenbaum A, Cheung P, Rajagopalan V, Yao S, Milgrim L, Kyprianou N Am J Clin Exp Urol. 2024; 12(5):255-265.

PMID: 39584003 PMC: 11578768. DOI: 10.62347/DZIU5992.


Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket.

Wallon L, Khan I, Teng K, Koide A, Zuberi M, Li J Proc Natl Acad Sci U S A. 2022; 119(43):e2204481119.

PMID: 36252024 PMC: 9618066. DOI: 10.1073/pnas.2204481119.


Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants.

Khan I, Koide A, Zuberi M, Ketavarapu G, Denbaum E, Teng K Cell Rep. 2022; 38(6):110322.

PMID: 35139380 PMC: 8936000. DOI: 10.1016/j.celrep.2022.110322.


Probing RAS Function with Monobodies.

Khan I, OBryan J Methods Mol Biol. 2021; 2262:281-302.

PMID: 33977484 PMC: 8121162. DOI: 10.1007/978-1-0716-1190-6_17.


Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis.

Khan I, Marelia-Bennet C, Lefler J, Zuberi M, Denbaum E, Koide A Small GTPases. 2021; 13(1):114-127.

PMID: 33949915 PMC: 9707541. DOI: 10.1080/21541248.2021.1906621.